After 1 year of treatment, significant reductions were observed vs placebo in both hsCRP and biopsy‐assessed fibrosis, but there was no significant treatment effect on either biopsy‐assessed NASH or ALT.59 Thus, although these limited observations should be interpreted with caution given the absence of mechanistic data, it is possible that ALT and hsCRP differ in their strengths of association with active steatohepatitis and fibrotic activity, with ALT potentially more closely linked to the former and hsCRP to the latter. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.